BR9809333A - Protease inhibitors - Google Patents

Protease inhibitors

Info

Publication number
BR9809333A
BR9809333A BR9809333-9A BR9809333A BR9809333A BR 9809333 A BR9809333 A BR 9809333A BR 9809333 A BR9809333 A BR 9809333A BR 9809333 A BR9809333 A BR 9809333A
Authority
BR
Brazil
Prior art keywords
disease
protease inhibitors
compounds
arthritis
oesteoarthritis
Prior art date
Application number
BR9809333-9A
Other languages
Portuguese (pt)
Inventor
Stacie Marie Halbert
Daniel Frank Veber
Evelyne Michaud
Scott Kevin Thompson
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of BR9809333A publication Critical patent/BR9809333A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

"INIBIDORES DE PROTEASES" A presente invenção fornece os compostos de fórmula (I), os quais inibem proteases, inclusive a catepsina K, composições farmacêuticas desses compostos, e método para tratar com eles as doenças de excessiva perda óssea ou degradação de cartilagem ou matriz, inclusive a osteoporose; doença gengival, inclusive gengivite e periodontite; artrite, mais especificamente, oesteoartrite e artrite reumatóide; doença de Paget; hipercalcemia maligna; e doença do metabolismo ósseo."PROTEASE INHIBITORS" The present invention provides the compounds of formula (I), which inhibit proteases, including cathepsin K, pharmaceutical compositions of these compounds, and a method of treating with them diseases of excessive bone loss or degradation of cartilage or matrix , including osteoporosis; gum disease, including gingivitis and periodontitis; arthritis, more specifically, Oesteoarthritis and rheumatoid arthritis; Paget's disease; malignant hypercalcemia; and bone metabolism disease.

BR9809333-9A 1997-04-29 1998-04-29 Protease inhibitors BR9809333A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4506797P 1997-04-29 1997-04-29
PCT/US1998/008740 WO1998048799A1 (en) 1997-04-29 1998-04-29 Protease inhibitors

Publications (1)

Publication Number Publication Date
BR9809333A true BR9809333A (en) 2000-07-04

Family

ID=21935831

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9809333-9A BR9809333A (en) 1997-04-29 1998-04-29 Protease inhibitors

Country Status (18)

Country Link
EP (1) EP1019046A4 (en)
JP (1) JP2002504097A (en)
KR (1) KR20010020391A (en)
CN (1) CN1261276A (en)
AR (1) AR012622A1 (en)
AU (1) AU7365198A (en)
BR (1) BR9809333A (en)
CA (1) CA2287989A1 (en)
CO (1) CO4940477A1 (en)
HU (1) HUP0001294A3 (en)
IL (1) IL132629A0 (en)
MA (1) MA26487A1 (en)
NO (1) NO995268L (en)
PE (1) PE69099A1 (en)
PL (1) PL337725A1 (en)
TR (1) TR199902703T2 (en)
WO (1) WO1998048799A1 (en)
ZA (1) ZA983522B (en)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR017219A1 (en) 1997-12-19 2001-08-22 Smithkline Beecham Corp IMIDAZOL DERIVATIVES 1,4,5 SUBSTITUTES, COMPOSITIONS THAT INCLUDE THEM, PROCEDURE FOR THE PREPARATION OF SUCH DERIVATIVES, USE OF DERIVATIVES TO MANUFACTURE OF A MEDICINAL PRODUCT
US6100282A (en) * 1998-01-02 2000-08-08 Hoffman-La Roche Inc. Thiazole derivatives
MA26618A1 (en) * 1998-04-09 2004-12-20 Smithkline Beecham Corp PHARMACEUTICAL COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF MALARIA
US6858617B2 (en) 1998-05-26 2005-02-22 Smithkline Beecham Corporation Substituted imidazole compounds
ATE258055T1 (en) 1998-11-04 2004-02-15 Smithkline Beecham Corp PYRIDINE-4-YL OR PYRIMIDINE-4-YL SUBSTITUTED PYRAZINE
CO5150165A1 (en) * 1998-11-13 2002-04-29 Smithkline Beecham Plc PROTEASE INHIBITORS: KATEPSIN K TYPE
US20030144175A1 (en) 1998-12-23 2003-07-31 Smithkline Beecham Corporation Protease inhibitors
JP2003513924A (en) 1999-11-10 2003-04-15 スミスクライン・ビーチャム・コーポレイション Protease inhibitor
US6583137B1 (en) 1999-11-10 2003-06-24 Smithkline Beecham Corporation Protease inhibitors
WO2001034599A1 (en) 1999-11-10 2001-05-17 Smithkline Beecham Corporation Protease inhibitors
US6797720B2 (en) 1999-12-03 2004-09-28 Ono Pharmaceutical Co., Ltd. 1,3,4-oxadiazoline derivative and an agent comprising its derivative as active ingredient
KR20020062312A (en) * 1999-12-03 2002-07-25 오노 야꾸힝 고교 가부시키가이샤 1,3,4-oxadiazoline derivatives and drugs containing these derivatives as the active ingredient
CN1416346A (en) 2000-03-21 2003-05-07 史密丝克莱恩比彻姆公司 Peotease inhibitors
EP1465862A1 (en) 2002-01-17 2004-10-13 SmithKline Beecham Corporation Cycloalkyl ketoamides derivatives useful as cathepsin k inhibitors
CA2490468A1 (en) * 2002-07-04 2004-01-22 Aventis Pharma S.A. Novel thiophene acyl hydrazino derivatives, method for preparing same, use thereof as medicines, pharmaceutical compositions and novel use
KR100962972B1 (en) 2002-07-26 2010-06-09 주식회사유한양행 1-phenylpiperidin-3-one derivatives and processes for the preparation thereof
WO2011015524A2 (en) * 2009-08-03 2011-02-10 Bayer Cropscience Ag Fungicide heterocycles derivatives
ES2779748T3 (en) * 2012-08-23 2020-08-19 Janssen Biopharma Inc Compounds for the treatment of paramyxovirus infections
CN114716426A (en) 2013-08-21 2022-07-08 詹森生物制药有限公司 Antiviral compounds
MA41614A (en) 2015-02-25 2018-01-02 Alios Biopharma Inc ANTIVIRAL COMPOUNDS

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ132798A3 (en) * 1995-10-30 1999-02-17 Smithkline Beecham Corporation Protease inhibitors

Also Published As

Publication number Publication date
WO1998048799A1 (en) 1998-11-05
CA2287989A1 (en) 1998-11-05
KR20010020391A (en) 2001-03-15
EP1019046A4 (en) 2002-11-27
HUP0001294A2 (en) 2001-04-28
EP1019046A1 (en) 2000-07-19
ZA983522B (en) 1998-10-29
PE69099A1 (en) 1999-09-26
HUP0001294A3 (en) 2001-06-28
AR012622A1 (en) 2000-11-08
CO4940477A1 (en) 2000-07-24
TR199902703T2 (en) 2000-02-21
NO995268D0 (en) 1999-10-28
NO995268L (en) 1999-11-15
AU7365198A (en) 1998-11-24
MA26487A1 (en) 2004-12-20
IL132629A0 (en) 2001-03-19
PL337725A1 (en) 2000-08-28
JP2002504097A (en) 2002-02-05
CN1261276A (en) 2000-07-26

Similar Documents

Publication Publication Date Title
BR9809333A (en) Protease inhibitors
AP9801222A0 (en) Proatease inhibitors.
NO20013124L (en) Protease inhibitors
BR0109356A (en) Protease Inhibitors
NZ537853A (en) Inhibitors of cathepsin K and related cysteine protesases of the CA clan
BR9804437A (en) Compounds for osteoporosis
BR9815469A (en) Protease inhibitors
WO1999059526A3 (en) Protease inhibitors
EA200300018A1 (en) PROTEAS INHIBITORS
UY26088A1 (en) PROTEASE INHIBITORS
UY26026A1 (en) PROTEASE INHIBITORS
WO2002092563A3 (en) Protease inhibitors
PT640098E (en) CANINE CORONAVIRUS GENE AND ITS USES
UY27032A1 (en) PROTEASE INHIBITORS
NZ324101A (en) Protease inhibitors, pharmaceutical compositions and use thereof
ECSP982481A (en) PROTEASE INHIBITORS
ECSP982486A (en) PROTEASE INHIBITORS II
AR004703A1 (en) HYDRAZIDIL, BIS-HYDRAZIL AND BIS-AMINOMETIL-CARBONIL, PROTEASE INHIBITORS, A PHARMACEUTICAL COMPOSITION, METHOD FOR INHIBITING PROTEASES, AND USE IN THE PREPARATION OF MEDICINES.
ECSP003403A (en) PROTEASE INHIBITORS XI
ECSP982493A (en) PROTEASE INHIBITORS III
ECSP992959A (en) BIS-AMINOMETIL CARBONYL PROTEASE INHIBITORS
AR021971A1 (en) PROTEASE INHIBITORS
UY24550A1 (en) PROTEASE INHIBITORS
ECSP993293A (en) PROTEASE INHIBITORS VIII
UY26771A1 (en) PROTEASE INHIBITORS

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A, 6A, 7A, 8A E 9A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 1889 DE 20/03/2007.